Drugeluting PowerPoint PPT Presentations

Drugeluting stents and Multivessel disease PCI

Outcomes with drugeluting stents in acute coronary syndromes

Significant human systemic experience in prevention of allograft rejection ... may further reduce restenosis, particularly at the ostium of the side branch...

Complex Coronary Intervention in the. Drug-Eluting Stent Era. Two ... VELVET/6mo. 23.4. 0.97. VENUS/6mo. 21.0. 0.80. RAVEL-Ctrl/6mo. 28.2. 1.00. SIRIUS-Ctrl/8mo ...

Brachytherapy; ISR outside-stent stenosis as 'edge effect' or what simulate the 'candy wrapper. ... 4 brachytherapy and 3 totally occluded. A 18 mm Bx VELOCITY, ...

Roxanne A. Rodney. American College of Cardiology. 53rd Annual Scientific Session ... Roxanne A. Rodney: Cordis enployee. Presenter Disclosure Information ...

Complex Coronary Intervention in the DrugEluting Stent Era Supplemental Slides

... small coronary vessels, angina pectoris, and significant stenosis in a native coronary vessel ... Unstable angina (%) 0.92. 56. 55. Hypercholesterolemia ...

with financial supported in part by. Deutsches Herzzentrum Munich and in part by ... as diameter stenosis 50% measured by QCA in the area from left main ostium to ...

Long Term Clinical Outcomes Following Drug-Eluting and Bare Metal ... History of Neoplasm (%) 2.1. 3.2 0.001. History of GI Bleeding (%) 1.6. 2.4 0.001 ...

... AND CLINICAL DATA ON PATIENTS WHO WERE DISCHARGED WITH THE DIAGNOSIS OF ACUTE ... PARALLEL ANALYSIS OF DES vs BMS USE IN THE SAME TIME PERIOD (2003 AND 2004) ...

Drug-Eluting and Bare Metal Stenting for Acute Myocardial Infarction in Massachusetts ... Brigham and Women's Hospital, Harvard Medical School, ...

Ashley B. Boam, MSBE. Division of Cardiovascular Devices. Office of Device Evaluation ... Ashley Boam, Branch Chief (aab@cdrh.fda.gov) Joni Foy, Ph.D., Lead ...

MIDAS CONTAINS SOCIODEMOGRAPHIC AND CLINICAL DATA ON PATIENTS WHO WERE ... MIDAS DATA RECORDS FROM 2003 and 2004 SHOW THAT THE USE OF DRUG-ELUTING STENTS ...

The Drug-Eluting Balloon in healthcare market was valued at US$ 516.65 million in 2018 and it is projected to reach US$ 1,870.60 million by 2027; it is expected to grow at a CAGR of 15.6% from 2019 to 2027.

Next-Generation Drug-Eluting Stent market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Next-Generation Drug-Eluting Stent market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.

Some of the market players featured in the report are Pfizer Inc., Medtronic Inc., Merck & Co., Inc., Bayer AG, Johnson & Johnson, Abbott, SurModics Inc., AstraZeneca Plc., Boston Scientific Corporation

Global Drug-Eluting Bioabsorbable Stents Market size is driven by the increasing geriatric population, rising obesity rate and associated risk factors, and development of technologically advanced devices. Get more details @ https://goo.gl/Cm1a9v

Global Coronary Stents Market (Bare Metal, Drug-Eluting, Bioresorable) is forecasted to grow at a CAGR of 3.05% by 2021. The North American region remains the major market followed by Europe in the actual period, while APAC and ROW will witness strong growth in the forecast period. Rising development of bioresorbable stents combined with the growing awareness towards cardiovascular risks in developing countries. Cardiovascular diseases are witnessing growth on account of the rise in the lifestyle related diseases including obesity, diabetes, hypertension etc. See full report @ https://goo.gl/vaWZ3m.